Madrigal Pharmaceuticals, Inc. (MDGL)
USD 314.54
(-3.84%)
USD 314.54
(-3.84%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 235.21 Million USD | 42.4% |
| 2022 | 165.18 Million USD | 113.9% |
| 2021 | 77.22 Million USD | 64.22% |
| 2020 | 47.02 Million USD | 84.48% |
| 2019 | 25.49 Million USD | 201.88% |
| 2018 | 8.44 Million USD | -16.01% |
| 2017 | 10.05 Million USD | 109.46% |
| 2016 | 4.8 Million USD | -73.02% |
| 2015 | 17.78 Million USD | -49.95% |
| 2014 | 35.53 Million USD | -22.93% |
| 2013 | 46.11 Million USD | 64.97% |
| 2012 | 27.95 Million USD | 1.46% |
| 2011 | 27.55 Million USD | -9.93% |
| 2010 | 30.58 Million USD | 27.46% |
| 2009 | 23.99 Million USD | -84.62% |
| 2008 | 156.04 Million USD | 59.63% |
| 2007 | 97.75 Million USD | 72.9% |
| 2006 | 56.53 Million USD | 201.8% |
| 2005 | 18.73 Million USD | 33.21% |
| 2004 | 14.06 Million USD | 302.26% |
| 2003 | 3.49 Million USD | 0.0% |
| 2001 | 29 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 231.52 Million USD | -1.57% |
| 2024 Q3 | 296.11 Million USD | 22.02% |
| 2024 Q2 | 242.66 Million USD | 4.82% |
| 2023 Q2 | 198.95 Million USD | 9.13% |
| 2023 FY | 235.21 Million USD | 42.4% |
| 2023 Q1 | 182.31 Million USD | 10.37% |
| 2023 Q3 | 215.71 Million USD | 8.42% |
| 2023 Q4 | 235.21 Million USD | 9.04% |
| 2022 Q3 | 147.97 Million USD | 11.38% |
| 2022 Q4 | 165.18 Million USD | 11.63% |
| 2022 FY | 165.18 Million USD | 113.9% |
| 2022 Q2 | 132.85 Million USD | 72.73% |
| 2022 Q1 | 76.91 Million USD | -0.4% |
| 2021 Q2 | 57.3 Million USD | 16.52% |
| 2021 Q1 | 49.17 Million USD | 4.58% |
| 2021 Q3 | 69.81 Million USD | 21.83% |
| 2021 Q4 | 77.22 Million USD | 10.61% |
| 2021 FY | 77.22 Million USD | 64.22% |
| 2020 FY | 47.02 Million USD | 84.48% |
| 2020 Q4 | 47.02 Million USD | -5.79% |
| 2020 Q2 | 45.47 Million USD | 75.01% |
| 2020 Q1 | 25.98 Million USD | 1.93% |
| 2020 Q3 | 49.91 Million USD | 9.77% |
| 2019 FY | 25.49 Million USD | 201.88% |
| 2019 Q2 | 12.83 Million USD | 16.12% |
| 2019 Q3 | 15.9 Million USD | 23.91% |
| 2019 Q1 | 11.05 Million USD | 30.91% |
| 2019 Q4 | 25.49 Million USD | 60.27% |
| 2018 Q3 | 6.64 Million USD | 22.19% |
| 2018 Q1 | 6.29 Million USD | -37.4% |
| 2018 FY | 8.44 Million USD | -16.01% |
| 2018 Q2 | 5.43 Million USD | -13.63% |
| 2018 Q4 | 8.44 Million USD | 27.13% |
| 2017 Q4 | 10.05 Million USD | 17.96% |
| 2017 Q2 | 6.43 Million USD | 8.97% |
| 2017 Q1 | 5.9 Million USD | 23.04% |
| 2017 FY | 10.05 Million USD | 109.46% |
| 2017 Q3 | 8.52 Million USD | 32.43% |
| 2016 Q3 | 3.91 Million USD | 16.39% |
| 2016 FY | 4.8 Million USD | -73.02% |
| 2016 Q4 | 4.8 Million USD | 22.59% |
| 2016 Q1 | 8.63 Million USD | -51.43% |
| 2016 Q2 | 3.36 Million USD | -61.06% |
| 2015 Q3 | 30.64 Million USD | -5.88% |
| 2015 Q4 | 17.78 Million USD | -41.95% |
| 2015 FY | 17.78 Million USD | -49.95% |
| 2015 Q2 | 32.55 Million USD | -2.09% |
| 2015 Q1 | 33.25 Million USD | -6.44% |
| 2014 Q4 | 35.53 Million USD | -10.99% |
| 2014 Q1 | 43.96 Million USD | -4.67% |
| 2014 Q2 | 41.94 Million USD | -4.58% |
| 2014 Q3 | 39.92 Million USD | -4.82% |
| 2014 FY | 35.53 Million USD | -22.93% |
| 2013 Q1 | 37.09 Million USD | 32.72% |
| 2013 FY | 46.11 Million USD | 64.97% |
| 2013 Q4 | 46.11 Million USD | 9.66% |
| 2013 Q3 | 42.05 Million USD | 9.26% |
| 2013 Q2 | 38.48 Million USD | 3.75% |
| 2012 Q1 | 26.07 Million USD | -5.37% |
| 2012 Q3 | 25.42 Million USD | -4.78% |
| 2012 Q4 | 27.95 Million USD | 9.94% |
| 2012 FY | 27.95 Million USD | 1.46% |
| 2012 Q2 | 26.7 Million USD | 2.41% |
| 2011 Q3 | 29.28 Million USD | 0.35% |
| 2011 FY | 27.55 Million USD | -9.93% |
| 2011 Q4 | 27.55 Million USD | -5.93% |
| 2011 Q2 | 29.18 Million USD | -2.15% |
| 2011 Q1 | 29.82 Million USD | -2.49% |
| 2010 Q4 | 30.58 Million USD | -3.26% |
| 2010 Q3 | 31.62 Million USD | 85.66% |
| 2010 FY | 30.58 Million USD | 27.46% |
| 2010 Q2 | 17.03 Million USD | -11.08% |
| 2010 Q1 | 19.15 Million USD | -20.19% |
| 2009 Q1 | 172.88 Million USD | 10.79% |
| 2009 Q3 | 26.72 Million USD | -82.95% |
| 2009 Q4 | 23.99 Million USD | -10.2% |
| 2009 FY | 23.99 Million USD | -84.62% |
| 2009 Q2 | 156.77 Million USD | -9.32% |
| 2008 Q1 | 95.91 Million USD | -1.88% |
| 2008 Q4 | 156.04 Million USD | 24.46% |
| 2008 FY | 156.04 Million USD | 59.63% |
| 2008 Q3 | 125.37 Million USD | 28.89% |
| 2008 Q2 | 97.27 Million USD | 1.41% |
| 2007 FY | 97.75 Million USD | 72.9% |
| 2007 Q1 | 15.66 Million USD | -72.3% |
| 2007 Q2 | 19.13 Million USD | 22.22% |
| 2007 Q4 | 97.75 Million USD | 476.95% |
| 2007 Q3 | 16.94 Million USD | -11.47% |
| 2006 Q3 | 55.99 Million USD | 0.0% |
| 2006 Q4 | 56.53 Million USD | 0.97% |
| 2006 FY | 56.53 Million USD | 201.8% |
| 2005 Q4 | 18.73 Million USD | 0.0% |
| 2005 Q1 | 17.4 Million USD | 0.0% |
| 2005 FY | 18.73 Million USD | 33.21% |
| 2004 FY | 14.06 Million USD | 302.26% |
| 2003 FY | 3.49 Million USD | 0.0% |
| 2001 FY | 29 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AbCellera Biologics Inc. | 335.77 Million USD | 29.949% |
| Alkermes plc | 933.53 Million USD | 74.804% |
| Agenus Inc. | 462.29 Million USD | 49.12% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 94.193% |
| Aptorum Group Limited | 5.25 Million USD | -4374.524% |
| Ardelyx, Inc. | 130.76 Million USD | -79.878% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 50.832% |
| Bicycle Therapeutics plc | 224.41 Million USD | -4.813% |
| BioXcel Therapeutics, Inc. | 130.21 Million USD | -80.642% |
| ChromaDex Corporation | 26.5 Million USD | -787.332% |
| Chimerix, Inc. | 19.74 Million USD | -1091.259% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -568.656% |
| Caribou Biosciences, Inc. | 72.56 Million USD | -224.134% |
| CRISPR Therapeutics AG | 346.76 Million USD | 32.17% |
| Precision BioSciences, Inc. | 140.92 Million USD | -66.913% |
| Dyadic International, Inc. | 2.34 Million USD | -9949.085% |
| Eton Pharmaceuticals, Inc. | 16.26 Million USD | -1346.314% |
| Fortress Biotech, Inc. | 165.93 Million USD | -41.747% |
| Lantern Pharma Inc. | 2.73 Million USD | -8485.449% |
| HOOKIPA Pharma Inc. | 71.48 Million USD | -229.063% |
| Inhibikase Therapeutics, Inc. | 3.52 Million USD | -6565.694% |
| Incyte Corporation | 1.59 Billion USD | 85.228% |
| IO Biotech, Inc. | 17.55 Million USD | -1239.793% |
| Jaguar Health, Inc. | 45.86 Million USD | -412.829% |
| Novavax, Inc. | 2.57 Billion USD | 90.856% |
| Janux Therapeutics, Inc. | 36.05 Million USD | -552.321% |
| Opthea Limited | 264.6 Million USD | 11.106% |
| Ligand Pharmaceuticals Incorporated | 130.7 Million USD | -79.955% |
| ContextLogic Inc. | 206 Million USD | -14.182% |
| MiMedx Group, Inc. | 96.33 Million USD | -144.175% |
| Pyxis Oncology, Inc. | 48.02 Million USD | -389.805% |
| TransCode Therapeutics, Inc. | 3.52 Million USD | -6565.388% |
| NextCure, Inc. | 14.99 Million USD | -1468.407% |
| Ocuphire Pharma, Inc. | 4.04 Million USD | -5719.248% |
| Oncternal Therapeutics, Inc. | 6.67 Million USD | -3422.75% |
| Outlook Therapeutics, Inc. | 46.73 Million USD | -403.25% |
| Vaxcyte, Inc. | 167.44 Million USD | -40.469% |
| PDS Biotechnology Corporation | 33.25 Million USD | -607.216% |
| Pharming Group N.V. | 244.07 Million USD | 3.63% |
| Pieris Pharmaceuticals, Inc. | 11.92 Million USD | -1872.941% |
| Avidity Biosciences, Inc. | 127.79 Million USD | -84.061% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -3459.922% |
| Reviva Pharmaceuticals Holdings, Inc. | 6.6 Million USD | -3459.922% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -185.34% |
| Sol-Gel Technologies Ltd. | 6.64 Million USD | -3440.78% |
| Acelyrin, Inc. | 86.35 Million USD | -172.387% |
| Salarius Pharmaceuticals, Inc. | 1.29 Million USD | -18003.955% |
| SELLAS Life Sciences Group, Inc. | 14.37 Million USD | -1535.816% |
| Summit Therapeutics Inc. | 125.25 Million USD | -87.785% |
| Sensei Biotherapeutics, Inc. | 9.47 Million USD | -2381.422% |
| Senti Biosciences, Inc. | 52.57 Million USD | -347.422% |
| Stoke Therapeutics, Inc. | 68.77 Million USD | -241.995% |
| Syros Pharmaceuticals, Inc. | 151.51 Million USD | -55.244% |
| Alaunos Therapeutics, Inc. | 1.95 Million USD | -11925.256% |
| Telomir Pharmaceuticals, Inc. Common Stock | 1.33 Million USD | -17511.586% |
| Entrada Therapeutics, Inc. | 226.83 Million USD | -3.695% |
| VistaGen Therapeutics, Inc. | 9.36 Million USD | -2411.092% |
| Wave Life Sciences Ltd. | 227.44 Million USD | -3.416% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 52.435% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -2055.159% |
| Barinthus Biotherapeutics plc | 27.51 Million USD | -754.982% |
| Psyence Biomedical Ltd. | 12.1 Million USD | -1843.163% |
| Phathom Pharmaceuticals, Inc. | 486.6 Million USD | 51.662% |
| Immix Biopharma, Inc. | 3.72 Million USD | -6219.928% |
| Keros Therapeutics, Inc. | 37.81 Million USD | -522.062% |
| MEI Pharma, Inc. | 8.35 Million USD | -2715.248% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -710.663% |
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 32.328% |
| Rigel Pharmaceuticals, Inc. | 145.86 Million USD | -61.25% |
| Fortress Biotech, Inc. | 165.93 Million USD | -41.747% |
| Precigen, Inc. | 41.64 Million USD | -464.821% |
| Clearside Biomedical, Inc. | 49.93 Million USD | -371.088% |
| AlloVir, Inc. | 45.01 Million USD | -422.524% |
| C4 Therapeutics, Inc. | 130.33 Million USD | -80.466% |
| Fate Therapeutics, Inc. | 137.8 Million USD | -70.692% |
| ImmuCell Corporation | 18.81 Million USD | -1150.139% |
| IDEAYA Biosciences, Inc. | 28.22 Million USD | -733.324% |
| Onconetix, Inc. | 23.18 Million USD | -914.689% |
| PureTech Health plc | 125.58 Million USD | -87.298% |
| VYNE Therapeutics Inc. | 8.95 Million USD | -2528.089% |
| Elevation Oncology, Inc. | 34.28 Million USD | -586.115% |
| Kintara Therapeutics, Inc. | 2.44 Million USD | -9520.204% |
| Seer, Inc. | 39.36 Million USD | -497.521% |
| Verrica Pharmaceuticals Inc. | 61.83 Million USD | -280.396% |
| Innoviva, Inc. | 568.55 Million USD | 58.629% |
| Aadi Bioscience, Inc. | 27.22 Million USD | -763.868% |
| ESSA Pharma Inc. | 3.49 Million USD | -6629.878% |
| GlycoMimetics, Inc. | 6.9 Million USD | -3307.874% |
| GT Biopharma, Inc. | 6.63 Million USD | -3446.118% |
| Inhibrx Biosciences, Inc. | 264.39 Million USD | 11.035% |
| Akebia Therapeutics, Inc. | 272.28 Million USD | 13.615% |
| Catalyst Pharmaceuticals, Inc. | 84.02 Million USD | -179.93% |
| Longboard Pharmaceuticals, Inc. | 9.77 Million USD | -2306.528% |
| Orchestra BioMed Holdings, Inc. | 27.16 Million USD | -765.744% |
| Alzamend Neuro, Inc. | 3.22 Million USD | -7191.71% |
| Rocket Pharmaceuticals, Inc. | 73.76 Million USD | -218.861% |
| Aptose Biosciences Inc. | 15.8 Million USD | -1387.877% |
| ZyVersa Therapeutics, Inc. | 11.03 Million USD | -2030.622% |
| Soligenix, Inc. | 7.27 Million USD | -3133.225% |
| Century Therapeutics, Inc. | 175.94 Million USD | -33.689% |
| Kura Oncology, Inc. | 51.66 Million USD | -355.294% |
| TScan Therapeutics, Inc. | 121.28 Million USD | -93.94% |
| Intensity Therapeutics, Inc. | 4.13 Million USD | -5591.12% |
| Ocean Biomedical, Inc. | 6.61 Million USD | -3456.383% |
| CytomX Therapeutics, Inc. | 252.59 Million USD | 6.882% |
| Autolus Therapeutics plc | 263.9 Million USD | 10.872% |
| Mineralys Therapeutics, Inc. | 10.48 Million USD | -2143.98% |
| EyePoint Pharmaceuticals, Inc. | 88.86 Million USD | -164.699% |
| Eterna Therapeutics Inc. | 46.89 Million USD | -401.533% |
| Adaptive Biotechnologies Corporation | 352.85 Million USD | 33.34% |
| GRI Bio, Inc. | 2.69 Million USD | -8621.32% |
| Xenetic Biosciences, Inc. | 809.58 Thousand USD | -28953.651% |
| Tenaya Therapeutics, Inc. | 31.09 Million USD | -656.534% |
| IGM Biosciences, Inc. | 220.17 Million USD | -6.83% |
| INmune Bio, Inc. | 18.86 Million USD | -1147.026% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 8.291% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -782.875% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -8552.644% |
| Entero Therapeutics, Inc. | 3.28 Million USD | -7070.577% |
| Milestone Pharmaceuticals Inc. | 58.45 Million USD | -302.385% |
| X4 Pharmaceuticals, Inc. | 96.15 Million USD | -144.609% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 11.151% |
| Coherus BioSciences, Inc. | 823.02 Million USD | 71.421% |
| Verastem, Inc. | 71.18 Million USD | -230.426% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -378.311% |
| Pliant Therapeutics, Inc. | 38.57 Million USD | -509.71% |
| Tonix Pharmaceuticals Holding Corp. | 48.93 Million USD | -380.696% |
| Histogen Inc. | 5.69 Million USD | -4028.734% |
| Aprea Therapeutics, Inc. | 4.38 Million USD | -5263.319% |
| Surrozen, Inc. | 8.14 Million USD | -2787.833% |
| Organovo Holdings, Inc. | 2.74 Million USD | -8459.461% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -74842.809% |
| Ovid Therapeutics Inc. | 56.22 Million USD | -318.308% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | -1324.503% |
| CASI Pharmaceuticals, Inc. | 51.1 Million USD | -360.274% |
| Cadrenal Therapeutics, Inc. Common Stock | 826.87 Thousand USD | -28346.138% |
| Centessa Pharmaceuticals plc | 126.72 Million USD | -85.61% |
| Hepion Pharmaceuticals, Inc. | 10.81 Million USD | -2075.17% |
| Arcturus Therapeutics Holdings Inc. | 150.88 Million USD | -55.885% |
| BioRestorative Therapies, Inc. | 2.6 Million USD | -8921.207% |
| Apollomics, Inc. | 14.15 Million USD | -1561.937% |
| Amarin Corporation plc | 279.58 Million USD | 15.871% |
| Mesoblast Limited | 188.79 Million USD | -24.585% |
| Turnstone Biologics Corp. | 14.14 Million USD | -1562.525% |
| Kymera Therapeutics, Inc. | 180.78 Million USD | -30.105% |
| Synaptogenix, Inc. | 5.52 Million USD | -4153.826% |
| Tiziana Life Sciences Ltd | 6.64 Million USD | -3438.117% |
| Aurinia Pharmaceuticals Inc. | 170.1 Million USD | -38.273% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -2648.728% |
| Monopar Therapeutics Inc. | 1.75 Million USD | -13284.257% |
| Exelixis, Inc. | 678.44 Million USD | 65.33% |
| Better Therapeutics, Inc. | 23.84 Million USD | -886.553% |
| Nurix Therapeutics, Inc. | 164.04 Million USD | -43.383% |
| Apellis Pharmaceuticals, Inc. | 594.2 Million USD | 60.416% |
| NLS Pharmaceutics AG | 10.68 Million USD | -2102.336% |
| Dermata Therapeutics, Inc. | 1.62 Million USD | -14387.046% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -504.244% |
| Gritstone bio, Inc. | 125.91 Million USD | -86.798% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -1502.712% |
| TNF Pharmaceuticals, Inc. | 5.08 Million USD | -4522.347% |
| Avid Bioservices, Inc. | 275.66 Million USD | 14.675% |
| Insmed Incorporated | 1.66 Billion USD | 85.845% |
| Virpax Pharmaceuticals, Inc. | 7.69 Million USD | -2957.1% |
| MediWound Ltd. | 27.18 Million USD | -765.171% |
| OmniAb, Inc. | 87.4 Million USD | -169.124% |
| Alector, Inc. | 487.66 Million USD | 51.768% |
| Seres Therapeutics, Inc. | 403.45 Million USD | 41.7% |
| Checkpoint Therapeutics, Inc. | 18.42 Million USD | -1176.602% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | -512.967% |
| Zai Lab Limited | 240.17 Million USD | 2.066% |
| Revance Therapeutics, Inc. | 630.05 Million USD | 62.668% |
| Aura Biosciences, Inc. | 29.22 Million USD | -704.783% |
| Lyell Immunopharma, Inc. | 95.07 Million USD | -147.393% |
| Immunic, Inc. | 25.36 Million USD | -827.208% |
| Tarsus Pharmaceuticals, Inc. | 69.23 Million USD | -239.728% |
| Veracyte, Inc. | 93.71 Million USD | -150.978% |
| InMed Pharmaceuticals Inc. | 2.61 Million USD | -8889.048% |
| FibroGen, Inc. | 585.72 Million USD | 59.842% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -1253.127% |
| Adial Pharmaceuticals, Inc. | 653.07 Thousand USD | -35916.329% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.65 Million USD | -4059.062% |
| Jazz Pharmaceuticals plc | 7.65 Billion USD | 96.928% |
| Cyclacel Pharmaceuticals, Inc. | 8.19 Million USD | -2769.163% |
| Amylyx Pharmaceuticals, Inc. | 84.02 Million USD | -179.943% |
| TG Therapeutics, Inc. | 169.08 Million USD | -39.11% |
| Galecto, Inc. | 5.89 Million USD | -3889.383% |
| Calithera Biosciences, Inc. | 8.28 Million USD | -2739.377% |
| Fortrea Holdings Inc. | 2.61 Billion USD | 91.017% |
| KalVista Pharmaceuticals, Inc. | 28.82 Million USD | -716.092% |
| Aptevo Therapeutics Inc. | 12.62 Million USD | -1763.672% |
| XBiotech Inc. | 8.39 Million USD | -2701.167% |
| Jasper Therapeutics, Inc. | 14.67 Million USD | -1502.712% |
| Lyra Therapeutics, Inc. | 53.18 Million USD | -342.298% |
| Foghorn Therapeutics Inc. | 363.1 Million USD | 35.222% |
| Y-mAbs Therapeutics, Inc. | 26.88 Million USD | -774.922% |
| Theravance Biopharma, Inc. | 169 Million USD | -39.177% |
| Ultragenyx Pharmaceutical Inc. | 1.21 Billion USD | 80.65% |
| Metagenomi, Inc. Common Stock | 500.42 Million USD | 52.997% |
| Vaxxinity, Inc. | 30.94 Million USD | -660.128% |
| BioCryst Pharmaceuticals, Inc. | 972.48 Million USD | 75.813% |
| Gain Therapeutics, Inc. | 6.03 Million USD | -3800.014% |
| Cartesian Therapeutics, Inc. | 745.23 Million USD | 68.438% |
| NexImmune, Inc. | 5.08 Million USD | -4526.343% |
| Creative Medical Technology Holdings, Inc. | 371.39 Thousand USD | -63232.741% |
| Marker Therapeutics, Inc. | 3.07 Million USD | -7549.614% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 96.69% |
| Chemomab Therapeutics Ltd. | 5.15 Million USD | -4463.691% |
| Scopus BioPharma Inc. | 7.45 Million USD | -3055.357% |
| RAPT Therapeutics, Inc. | 26.29 Million USD | -794.554% |
| Ainos, Inc. | 7.39 Million USD | -3081.051% |
| Pluri Inc. | 34.11 Million USD | -589.534% |
| Prothena Corporation plc | 135.01 Million USD | -74.211% |
| Adaptimmune Therapeutics plc | 243.1 Million USD | 3.245% |
| Celularity Inc. | 102.92 Million USD | -128.521% |
| Rallybio Corporation | 9.43 Million USD | -2392.73% |
| Cue Biopharma, Inc. | 24.44 Million USD | -862.217% |
| MeiraGTx Holdings plc | 319.99 Million USD | 26.494% |
| Omeros Corporation | 403.25 Million USD | 41.671% |
| Humacyte, Inc. | 114.67 Million USD | -105.11% |
| Immunocore Holdings plc | 228.15 Million USD | -3.093% |
| Cocrystal Pharma, Inc. | 4.87 Million USD | -4724.903% |
| Cidara Therapeutics, Inc. | 76.74 Million USD | -206.508% |
| Blueprint Medicines Corporation | 918.64 Million USD | 74.395% |
| CalciMedica, Inc. | 4.02 Million USD | -5739.474% |
| Cabaletta Bio, Inc. | 17.45 Million USD | -1247.777% |
| Marinus Pharmaceuticals, Inc. | 154.14 Million USD | -52.595% |
| Scholar Rock Holding Corporation | 85.81 Million USD | -174.088% |
| Sana Biotechnology, Inc. | 277.79 Million USD | 15.328% |
| Pulmatrix, Inc. | 15.96 Million USD | -1373.495% |
| Elicio Therapeutics, Inc. | 15.77 Million USD | -1391.245% |
| Vigil Neuroscience, Inc. | 24.6 Million USD | -855.921% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 6.218% |
| Adlai Nortye Ltd. American Depositary Shares | 50.78 Million USD | -363.147% |
| Cytokinetics, Incorporated | 1.21 Billion USD | 80.571% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -640.062% |
| Nutriband Inc. | 1.07 Million USD | -21700.895% |
| Protara Therapeutics, Inc. | 10.63 Million USD | -2112.113% |
| Vor Biopharma Inc. | 59.1 Million USD | -297.966% |
| Roivant Sciences Ltd. | 773.95 Million USD | 69.609% |
| Evogene Ltd. | 17.99 Million USD | -1207.471% |
| ProKidney Corp. | 29.21 Million USD | -705.086% |
| Applied Therapeutics, Inc. | 71.97 Million USD | -226.781% |
| Hoth Therapeutics, Inc. | 704.98 Thousand USD | -33264.492% |
| BridgeBio Pharma, Inc. | 1.88 Billion USD | 87.548% |
| CorMedix Inc. | 11.91 Million USD | -1873.681% |
| BioLineRx Ltd. | 50.7 Million USD | -363.915% |
| Tango Therapeutics, Inc. | 149.45 Million USD | -57.377% |
| Galectin Therapeutics Inc. | 88.44 Million USD | -165.956% |
| Atai Life Sciences N.V. | 49.16 Million USD | -378.447% |
| Renovaro Biosciences Inc. | 31.15 Million USD | -655.045% |
| Aerovate Therapeutics, Inc. | 17.96 Million USD | -1209.509% |
| Zentalis Pharmaceuticals, Inc. | 124.63 Million USD | -88.721% |
| Sagimet Biosciences Inc. | 5.65 Million USD | -4060.134% |
| MediciNova, Inc. | 3.89 Million USD | -5944.219% |
| Praxis Precision Medicines, Inc. | 18.27 Million USD | -1186.799% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -15536.723% |
| GeoVax Labs, Inc. | 3.51 Million USD | -6582.442% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 40.791% |
| Biomea Fusion, Inc. | 30.69 Million USD | -666.419% |
| PTC Therapeutics, Inc. | 2.72 Billion USD | 91.358% |
| Mereo BioPharma Group plc | 15.96 Million USD | -1373.587% |
| Cullinan Oncology, Inc. | 31.2 Million USD | -653.867% |
| Syndax Pharmaceuticals, Inc. | 58.68 Million USD | -300.815% |
| Absci Corporation | 58.3 Million USD | -303.427% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -1134.849% |
| 4D Molecular Therapeutics, Inc. | 32.06 Million USD | -633.622% |
| Dyne Therapeutics, Inc. | 73.79 Million USD | -218.761% |
| Kiniksa Pharmaceuticals, Ltd. | 87.48 Million USD | -168.868% |
| Ventyx Biosciences, Inc. | 33.77 Million USD | -596.518% |
| Allakos Inc. | 74.79 Million USD | -214.487% |
| Imunon, Inc. | 8.53 Million USD | -2657.353% |
| Fulcrum Therapeutics, Inc. | 22.5 Million USD | -945.349% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -104.869% |
| BioAtla, Inc. | 48.98 Million USD | -380.166% |
| NLS Pharmaceutics AG | 10.68 Million USD | -2102.336% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -8363.98% |
| Allogene Therapeutics, Inc. | 130.6 Million USD | -80.097% |
| Larimar Therapeutics, Inc. | 14.21 Million USD | -1554.689% |
| XOMA Corporation | 145.58 Million USD | -61.57% |
| Kezar Life Sciences, Inc. | 33.66 Million USD | -598.69% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -242.085% |
| aTyr Pharma, Inc. | 31.59 Million USD | -644.419% |
| Aligos Therapeutics, Inc. | 61.82 Million USD | -280.464% |
| Akero Therapeutics, Inc. | 44.96 Million USD | -423.105% |
| Viridian Therapeutics, Inc. | 48.4 Million USD | -385.959% |
| Eliem Therapeutics, Inc. | 2.87 Million USD | -8095.61% |
| EyeGate Pharmaceuticals, Inc. | 8.15 Million USD | -2783.225% |
| Akari Therapeutics, Plc | 4.58 Million USD | -5031.195% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -1226.41% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 85.74% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -58134.548% |
| UroGen Pharma Ltd. | 243.52 Million USD | 3.412% |
| Sutro Biopharma, Inc. | 321.08 Million USD | 26.744% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -8417.438% |
| Orgenesis Inc. | 35.53 Million USD | -561.922% |
| Entera Bio Ltd. | 1.37 Million USD | -16956.853% |
| GH Research PLC | 6.7 Million USD | -3410.133% |
| Lisata Therapeutics, Inc. | 6.8 Million USD | -3359.029% |
| Reneo Pharmaceuticals, Inc. | 18.82 Million USD | -1149.41% |
| Xencor, Inc. | 283.55 Million USD | 17.049% |
| 60 Degrees Pharmaceuticals, Inc. | 2.98 Million USD | -7778.085% |
| Replimune Group, Inc. | 113.21 Million USD | -107.761% |
| Coeptis Therapeutics Holdings, Inc. | 3.75 Million USD | -6160.478% |
| Vanda Pharmaceuticals Inc. | 103.53 Million USD | -127.194% |
| Lexaria Bioscience Corp. | 403.9 Thousand USD | -58134.548% |
| Portage Biotech Inc. | 4.45 Million USD | -5185.708% |
| Cardio Diagnostics Holdings, Inc. | 1.5 Million USD | -15536.723% |
| Olema Pharmaceuticals, Inc. | 23.05 Million USD | -920.451% |
| OncoCyte Corporation | 49.29 Million USD | -377.127% |
| Qualigen Therapeutics, Inc. | 4.13 Million USD | -5585.886% |
| Processa Pharmaceuticals, Inc. | 797.48 Thousand USD | -29394.51% |
| Purple Biotech Ltd. | 10 Million USD | -2250.965% |
| CollPlant Biotechnologies Ltd. | 5.78 Million USD | -3965.226% |
| scPharmaceuticals Inc. | 57.26 Million USD | -310.775% |
| ProMIS Neurosciences, Inc. | 12.38 Million USD | -1798.721% |
| HilleVax, Inc. | 78.9 Million USD | -198.083% |
| NeuroSense Therapeutics Ltd. | 5.05 Million USD | -4557.703% |
| Tharimmune, Inc. | 1.81 Million USD | -12859.121% |
| Genprex, Inc. | 3.25 Million USD | -7127.995% |
| Neumora Therapeutics, Inc. Common Stock | 27.11 Million USD | -767.34% |
| Atossa Therapeutics, Inc. | 5.23 Million USD | -4392.246% |
| XTL Biopharmaceuticals Ltd. | 206 Thousand USD | -114081.553% |
| Virios Therapeutics, Inc. | 358.54 Thousand USD | -65501.816% |
| OKYO Pharma Limited | 7.42 Million USD | -3069.639% |
| Savara Inc. | 37.19 Million USD | -532.432% |
| Curis, Inc. | 57.61 Million USD | -308.273% |
| Daré Bioscience, Inc. | 26.32 Million USD | -793.336% |
| Carmell Therapeutics Corporation | 39.19 Million USD | -500.039% |
| Titan Pharmaceuticals, Inc. | 1.44 Million USD | -16189.058% |
| Achieve Life Sciences, Inc. | 20.81 Million USD | -1029.805% |
| BeiGene, Ltd. | 2.23 Billion USD | 89.47% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | -1004.82% |
| Revolution Medicines, Inc. Warrant | 262.39 Million USD | 10.359% |
| Protagonist Therapeutics, Inc. | 21.27 Million USD | -1005.641% |
| Erasca, Inc. | 78.61 Million USD | -199.213% |
| bluebird bio, Inc. | 424.62 Million USD | 44.607% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -35796.724% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 87.555% |
| DBV Technologies S.A. | 42.8 Million USD | -449.565% |
| Protagenic Therapeutics, Inc. | 655.25 Thousand USD | -35796.724% |
| Moderna, Inc. | 4.57 Billion USD | 94.855% |
| Vincerx Pharma, Inc. | 6.99 Million USD | -3262.602% |
| Fresh Tracks Therapeutics, Inc. | 1.65 Million USD | -14103.744% |
| Molecular Templates, Inc. | 31.17 Million USD | -654.592% |
| Acrivon Therapeutics, Inc. Common Stock | 17.07 Million USD | -1277.938% |
| Travere Therapeutics, Inc. | 588.1 Million USD | 60.005% |
| Monte Rosa Therapeutics, Inc. | 124.5 Million USD | -88.919% |
| Spruce Biosciences, Inc. | 27.43 Million USD | -757.288% |
| Celldex Therapeutics, Inc. | 36.45 Million USD | -545.2% |
| Cogent Biosciences, Inc. | 55.63 Million USD | -322.781% |
| MacroGenics, Inc. | 154.2 Million USD | -52.531% |
| RenovoRx, Inc. | 4.46 Million USD | -5166.771% |
| Adicet Bio, Inc. | 37.12 Million USD | -533.658% |
| Prime Medicine, Inc. | 60.78 Million USD | -286.992% |
| Aditxt, Inc. | 28.53 Million USD | -724.399% |
| Adagene Inc. | 45.16 Million USD | -420.738% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -130067.514% |
| Quantum-Si incorporated | 26.63 Million USD | -783.234% |
| Maravai LifeSciences Holdings, Inc. | 697.56 Million USD | 66.281% |
| Acurx Pharmaceuticals, Inc. | 3.04 Million USD | -7631.102% |
| Voyager Therapeutics, Inc. | 114.96 Million USD | -104.603% |
| SciSparc Ltd. | 1.59 Million USD | -14646.959% |
| Vericel Corporation | 127.7 Million USD | -84.185% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -4126.747% |
| Minerva Neurosciences, Inc. | 85.35 Million USD | -175.561% |
| Generation Bio Co. | 171.63 Million USD | -37.047% |
| Astria Therapeutics, Inc. | 11.55 Million USD | -1936.485% |
| Black Diamond Therapeutics, Inc. | 41.83 Million USD | -462.296% |
| Arcutis Biotherapeutics, Inc. | 252.69 Million USD | 6.919% |
| Invivyd, Inc. | 51.71 Million USD | -354.845% |
| Relay Therapeutics, Inc. | 91.97 Million USD | -155.731% |
| Quoin Pharmaceuticals, Ltd. | 6.5 Million USD | -3515.756% |
| Spero Therapeutics, Inc. | 75.49 Million USD | -211.558% |
| Artelo Biosciences, Inc. | 1.02 Million USD | -22937.61% |
| 2seventy bio, Inc. | 310.12 Million USD | 24.155% |
| ADMA Biologics, Inc. | 193.97 Million USD | -21.259% |
| Clene Inc. | 38.95 Million USD | -503.872% |
| Capricor Therapeutics, Inc. | 36.13 Million USD | -550.97% |
| Boundless Bio, Inc. Common Stock | 256.97 Million USD | 8.468% |
| GeoVax Labs, Inc. | 3.51 Million USD | -6582.442% |
| Recursion Pharmaceuticals, Inc. | 190.26 Million USD | -23.626% |
| Citius Pharmaceuticals, Inc. | 12.17 Million USD | -1831.203% |
| Contineum Therapeutics, Inc. Class A Common Stock | 198.32 Million USD | -18.602% |
| Relmada Therapeutics, Inc. | 12.19 Million USD | -1828.806% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | -388.899% |
| ALX Oncology Holdings Inc. | 52.84 Million USD | -345.135% |
| Vir Biotechnology, Inc. | 369.85 Million USD | 36.404% |
| Evaxion Biotech A/S | 17.61 Million USD | -1235.117% |
| Ocular Therapeutix, Inc. | 160.92 Million USD | -46.16% |
| Verve Therapeutics, Inc. | 153.18 Million USD | -53.548% |
| Trevena, Inc. | 48.26 Million USD | -387.369% |
| Surrozen, Inc. | 8.14 Million USD | -2787.833% |
| Tyra Biosciences, Inc. | 21.59 Million USD | -989.206% |
| Cingulate Inc. | 10.36 Million USD | -2170.216% |
| Galmed Pharmaceuticals Ltd. | 2.75 Million USD | -8453.236% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -530.736% |
| Tenax Therapeutics, Inc. | 3.58 Million USD | -6458.279% |
| Terns Pharmaceuticals, Inc. | 13.15 Million USD | -1688.7% |
| ACADIA Pharmaceuticals Inc. | 317.2 Million USD | 25.847% |
| Connect Biopharma Holdings Limited | 24.84 Million USD | -846.573% |
| Clearmind Medicine Inc. | 3.61 Million USD | -6415.609% |
| Kronos Bio, Inc. | 54.2 Million USD | -333.966% |
| Bolt Biotherapeutics, Inc. | 47.04 Million USD | -399.998% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -933.466% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -1071.91% |
| Statera Biopharma, Inc. | 22.67 Million USD | -937.261% |
| ImmunityBio, Inc. | 1.09 Billion USD | 78.428% |
| Korro Bio, Inc. | 51.75 Million USD | -354.502% |
| Kineta, Inc. | 7.22 Million USD | -3156.909% |
| BioVie Inc. | 9.7 Million USD | -2324.354% |
| Codexis, Inc. | 49.94 Million USD | -370.937% |
| Celularity Inc. | 102.92 Million USD | -128.521% |
| Crinetics Pharmaceuticals, Inc. | 96.24 Million USD | -144.386% |
| Celcuity Inc. | 51.45 Million USD | -357.169% |
| Virax Biolabs Group Limited | 345.19 Thousand USD | -68039.655% |
| Cibus, Inc. | 206.11 Million USD | -14.117% |
| Eledon Pharmaceuticals, Inc. | 42.47 Million USD | -453.77% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -793.026% |
| IN8bio, Inc. | 8.77 Million USD | -2581.418% |
| Kodiak Sciences Inc. | 213.59 Million USD | -10.124% |
| Annexon, Inc. | 47.11 Million USD | -399.202% |
| Adverum Biotechnologies, Inc. | 89.54 Million USD | -162.689% |
| Assembly Biosciences, Inc. | 96.37 Million USD | -144.069% |
| Avalo Therapeutics, Inc. | 13.68 Million USD | -1618.27% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 90.965% |
| Eyenovia, Inc. | 19.78 Million USD | -1089.134% |
| Puma Biotechnology, Inc. | 177.08 Million USD | -32.825% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -2962.284% |
| Xilio Therapeutics, Inc. | 24.09 Million USD | -876.032% |
| Arcellx, Inc. | 339.75 Million USD | 30.769% |
| Cardiff Oncology, Inc. | 11.89 Million USD | -1876.92% |
| Enanta Pharmaceuticals, Inc. | 245.54 Million USD | 4.205% |
| Regulus Therapeutics Inc. | 9.56 Million USD | -2359.626% |
| Moolec Science SA | 13.94 Million USD | -1586.683% |
| Acumen Pharmaceuticals, Inc. | 43.15 Million USD | -445.082% |
| Geron Corporation | 146.12 Million USD | -60.965% |
| LAVA Therapeutics N.V. | 50.53 Million USD | -365.475% |
| Royalty Pharma plc | 6.29 Billion USD | 96.265% |
| Atea Pharmaceuticals, Inc. | 39.77 Million USD | -491.347% |
| Greenwich LifeSciences, Inc. | 294.4 Thousand USD | -79794.431% |
| TFF Pharmaceuticals, Inc. | 2.46 Million USD | -9460.449% |
| Mersana Therapeutics, Inc. | 189.15 Million USD | -24.349% |
| Humacyte, Inc. | 114.67 Million USD | -105.11% |
| Structure Therapeutics Inc. | 29.05 Million USD | -709.659% |
| 89bio, Inc. | 59.96 Million USD | -292.265% |
| PMV Pharmaceuticals, Inc. | 26.46 Million USD | -788.841% |
| Avenue Therapeutics, Inc. | 1.19 Million USD | -19566.722% |
| Genelux Corporation | 8.42 Million USD | -2693.515% |
| Trevi Therapeutics, Inc. | 6.85 Million USD | -3330.776% |
| Lexicon Pharmaceuticals, Inc. | 136.31 Million USD | -72.547% |
| Notable Labs, Ltd. | 4.42 Million USD | -5213.169% |
| Liquidia Corporation | 73.13 Million USD | -221.603% |
| Mustang Bio, Inc. | 17.61 Million USD | -1235.002% |
| Immunovant, Inc. | 48.95 Million USD | -380.47% |
| Quantum-Si incorporated | 26.63 Million USD | -783.234% |
| Arbutus Biopharma Corporation | 38.38 Million USD | -512.808% |
| DiaMedica Therapeutics Inc. | 3.1 Million USD | -7480.213% |
| Vera Therapeutics, Inc. | 73.86 Million USD | -218.455% |
| Acasti Pharma Inc. | 11.55 Million USD | -1935.251% |
| MiNK Therapeutics, Inc. | 22.6 Million USD | -940.414% |
| Pasithea Therapeutics Corp. | 2.71 Million USD | -8552.644% |
| Xenon Pharmaceuticals Inc. | 36.87 Million USD | -537.834% |
| Elevai Labs, Inc. Common Stock | 1.36 Million USD | -17159.081% |
| NeuroBo Pharmaceuticals, Inc. | 6.09 Million USD | -3758.497% |
| Tempest Therapeutics, Inc. | 24.83 Million USD | -847.107% |
| Soleno Therapeutics, Inc. | 23.18 Million USD | -914.553% |
| PepGen Inc. | 34.63 Million USD | -579.201% |
| Moleculin Biotech, Inc. | 12.14 Million USD | -1836.874% |
| United Therapeutics Corporation | 1.18 Billion USD | 80.104% |
| Nuvectis Pharma, Inc. | 6.98 Million USD | -3267.898% |
| Solid Biosciences Inc. | 38.45 Million USD | -511.613% |
| BriaCell Therapeutics Corp. | 8.55 Million USD | -2648.728% |
| Immuneering Corporation | 12 Million USD | -1858.753% |
| Lixte Biotechnology Holdings, Inc. | 313.85 Thousand USD | -74842.809% |
| Silo Pharma, Inc. | 1.56 Million USD | -14888.753% |
| Belite Bio, Inc | 4.21 Million USD | -5485.704% |
| XOMA Corporation | 145.58 Million USD | -61.57% |
| ARS Pharmaceuticals, Inc. | 2.42 Million USD | -9587.562% |
| Bionomics Limited | 10.15 Million USD | -2215.39% |
| Apogee Therapeutics, Inc. | 21.49 Million USD | -994.477% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -926.553% |
| uniQure N.V. | 624.01 Million USD | 62.307% |
| Cassava Sciences, Inc. | 14.19 Million USD | -1557.02% |
| Estrella Immunopharma, Inc. | 180.7 Thousand USD | -130067.514% |
| Poseida Therapeutics, Inc. | 170.18 Million USD | -38.212% |
| Forte Biosciences, Inc. | 3.66 Million USD | -6316.094% |
| Anebulo Pharmaceuticals, Inc. | 260.58 Thousand USD | -90164.522% |
| Enlivex Therapeutics Ltd. | 6.74 Million USD | -3386.201% |
| Conduit Pharmaceuticals Inc. | 7.68 Million USD | -2962.284% |
| SeaStar Medical Holding Corporation | 17.38 Million USD | -1253.127% |
| FibroBiologics, Inc. Common Stock | 10.56 Million USD | -2125.719% |
| Altimmune, Inc. | 16.54 Million USD | -1322.006% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 61.921% |
| Alpha Tau Medical Ltd. | 22.91 Million USD | -926.553% |
| Compugen Ltd. | 55.77 Million USD | -321.719% |
| Peak Bio, Inc. | 20.75 Million USD | -1033.378% |
| Zevra Therapeutics, Inc. | 110.46 Million USD | -112.935% |
| Benitec Biopharma Inc. | 4.96 Million USD | -4640.306% |
| Spyre Therapeutics, Inc. | 157.84 Million USD | -49.018% |
| NKGen Biotech, Inc. Common Stock | 75.17 Million USD | -212.893% |
| Zura Bio Limited | 21.29 Million USD | -1004.706% |
| PolyPid Ltd. | 17.46 Million USD | -1246.542% |
| Aileron Therapeutics, Inc. | 112.39 Million USD | -109.267% |
| NKGen Biotech, Inc. Warrants | 75.17 Million USD | -212.893% |
| Instil Bio, Inc. | 99.8 Million USD | -135.683% |
| argenx SE | 444.95 Million USD | 47.137% |
| Immunome, Inc. | 28.65 Million USD | -720.762% |
| Compass Therapeutics, Inc. | 8.33 Million USD | -2721.327% |
| Verona Pharma plc | 58.84 Million USD | -299.745% |
| enGene Holdings Inc. Warrants | 14.47 Million USD | -1525.192% |
| Shattuck Labs, Inc. | 14.85 Million USD | -1482.973% |
| CervoMed Inc. | 2.59 Million USD | -8961.515% |
| LENZ Therapeutics, Inc. | 4.87 Million USD | -4725.892% |
| Plus Therapeutics, Inc. | 12.73 Million USD | -1746.844% |
| Dianthus Therapeutics, Inc. | 10.53 Million USD | -2132.691% |
| Moolec Science SA | 13.94 Million USD | -1586.683% |
| Enveric Biosciences, Inc. | 2.34 Million USD | -9936.851% |
| Inovio Pharmaceuticals, Inc. | 55.59 Million USD | -323.083% |
| AnaptysBio, Inc. | 364.28 Million USD | 35.432% |
| Design Therapeutics, Inc. | 11.95 Million USD | -1867.33% |
| Leap Therapeutics, Inc. | 12.68 Million USD | -1754.415% |
| NeurAxis, Inc. | 1.91 Million USD | -12197.234% |
| Seelos Therapeutics, Inc. | 38.92 Million USD | -504.228% |
| Lumos Pharma, Inc. | 13.33 Million USD | -1664.149% |
| Achilles Therapeutics plc | 19.08 Million USD | -1132.326% |
| enGene Holdings Inc. Common Stock | 14.47 Million USD | -1525.192% |
| 180 Life Sciences Corp. | 5.38 Million USD | -4266.157% |
| Opiant Pharmaceuticals, Inc. | 23.58 Million USD | -897.177% |
| CERo Therapeutics Holdings, Inc. | 22.75 Million USD | -933.466% |
| Nutriband Inc. | 1.07 Million USD | -21700.895% |
| ORIC Pharmaceuticals, Inc. | 30.59 Million USD | -668.723% |
| CG Oncology, Inc. Common stock | 14.51 Million USD | -1520.936% |
| Fractyl Health, Inc. Common Stock | 401.27 Million USD | 41.383% |
| Rani Therapeutics Holdings, Inc. | 32.47 Million USD | -624.337% |
| MoonLake Immunotherapeutics | 13.04 Million USD | -1702.531% |
| Palisade Bio, Inc. | 2.73 Million USD | -8487.587% |
| Tourmaline Bio, Inc. | 5.25 Million USD | -4377.708% |
| Beam Therapeutics Inc. | 478.38 Million USD | 50.832% |
| Neurogene Inc. | 36.54 Million USD | -543.558% |
| Mirum Pharmaceuticals, Inc. | 397.95 Million USD | 40.894% |
| AEON Biopharma, Inc. | 159.88 Million USD | -47.111% |
| CARGO Therapeutics, Inc. Common Stock | 47.65 Million USD | -393.629% |
| Sesen Bio, Inc. | 30.98 Million USD | -659.147% |
| Enliven Therapeutics, Inc. | 25.96 Million USD | -806.028% |
| Kiora Pharmaceuticals, Inc. | 7.6 Million USD | -2994.019% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -20.168% |
| Taysha Gene Therapies, Inc. | 192.05 Million USD | -22.471% |
| Athira Pharma, Inc. | 30.05 Million USD | -682.56% |
| Vaccinex, Inc. | 5.94 Million USD | -3858.499% |
| HCW Biologics Inc. | 15.05 Million USD | -1462.682% |
| XOMA Corporation | 145.58 Million USD | -61.57% |
| Nektar Therapeutics | 267.04 Million USD | 11.92% |
| Arvinas, Inc. | 644.6 Million USD | 63.51% |
| Tevogen Bio Holdings Inc. | 17.73 Million USD | -1226.41% |
| Merus N.V. | 102.15 Million USD | -130.261% |
| Omega Therapeutics, Inc. | 146.35 Million USD | -60.72% |
| Quince Therapeutics, Inc. | 95.12 Million USD | -147.281% |
| Rezolute, Inc. | 11.73 Million USD | -1904.551% |
| Clene Inc. | 38.95 Million USD | -503.872% |
| Indaptus Therapeutics, Inc. | 2.84 Million USD | -8160.717% |
| BeyondSpring Inc. | 48.26 Million USD | -387.298% |
| Synlogic, Inc. | 32.89 Million USD | -615.045% |
| Allarity Therapeutics, Inc. | 14.61 Million USD | -1509.622% |
| Phio Pharmaceuticals Corp. | 1.63 Million USD | -14294.982% |
| Peak Bio, Inc. | 20.75 Million USD | -1033.378% |
| Werewolf Therapeutics, Inc. | 63.45 Million USD | -270.655% |
| Krystal Biotech, Inc. | 39.71 Million USD | -492.27% |
| Karyopharm Therapeutics Inc. | 376.64 Million USD | 37.55% |
| SpringWorks Therapeutics, Inc. | 99.56 Million USD | -136.232% |
| Lipella Pharmaceuticals Inc. | 432.72 Thousand USD | -54256.336% |
| MannKind Corporation | 721.36 Million USD | 67.393% |
| Ikena Oncology, Inc. | 22.33 Million USD | -953.118% |
| Cyclerion Therapeutics, Inc. | 2.08 Million USD | -11175.839% |
| Gyre Therapeutics, Inc. | 102.59 Million USD | -129.276% |
| Gossamer Bio, Inc. | 249.14 Million USD | 5.592% |
| CohBar, Inc. | 1.03 Million USD | -22655.936% |
| Cognition Therapeutics, Inc. | 10.68 Million USD | -2100.524% |
| NRx Pharmaceuticals, Inc. | 19.04 Million USD | -1134.849% |
| Legend Biotech Corporation | 589.93 Million USD | 60.129% |
| Mural Oncology plc | 37.92 Million USD | -520.159% |
| Biora Therapeutics, Inc. | 132.63 Million USD | -77.338% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -10147.494% |
| Disc Medicine, Inc. | 22.87 Million USD | -928.258% |
| Champions Oncology, Inc. | 28.03 Million USD | -739.001% |
| REGENXBIO Inc. | 262.22 Million USD | 10.302% |
| Ensysce Biosciences, Inc. | 3.35 Million USD | -6901.767% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -1776.608% |
| Cellectar Biosciences, Inc. | 13.43 Million USD | -1651.195% |
| Edgewise Therapeutics, Inc. | 21.2 Million USD | -1009.238% |
| Vaxart, Inc. | 34.02 Million USD | -591.298% |
| PharmaCyte Biotech, Inc. | 20.38 Million USD | -1053.617% |
| Aldeyra Therapeutics, Inc. | 28.53 Million USD | -724.39% |
| Cellectis S.A. | 249.57 Million USD | 5.754% |
| Longeveron Inc. | 5.33 Million USD | -4307.233% |
| Repare Therapeutics Inc. | 41.81 Million USD | -462.457% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 90.221% |
| Inozyme Pharma, Inc. | 60.36 Million USD | -289.634% |
| Revolution Medicines, Inc. | 262.39 Million USD | 10.359% |
| Nymox Pharmaceutical Corporation | 2.1 Million USD | -11063.455% |
| Third Harmonic Bio, Inc. | 8.62 Million USD | -2626.803% |
| ArriVent BioPharma, Inc. Common Stock | 11.8 Million USD | -1893.17% |
| AN2 Therapeutics, Inc. | 14.04 Million USD | -1574.955% |
| Anixa Biosciences, Inc. | 2.15 Million USD | -10835.1% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 95.433% |
| Denali Therapeutics Inc. | 122.96 Million USD | -91.288% |
| Revelation Biosciences, Inc. | 5.56 Million USD | -4126.747% |
| Veru Inc. | 32.81 Million USD | -616.838% |
| Corvus Pharmaceuticals, Inc. | 6.86 Million USD | -3324.283% |
| Cingulate Inc. | 10.36 Million USD | -2170.216% |
| Passage Bio, Inc. | 39.26 Million USD | -499.088% |
| Context Therapeutics Inc. | 4.19 Million USD | -5511.402% |
| Exicure, Inc. | 8.54 Million USD | -2651.363% |
| Day One Biopharmaceuticals, Inc. | 29.5 Million USD | -697.119% |
| Oramed Pharmaceuticals Inc. | 10.48 Million USD | -2143.124% |
| Scinai Immunotherapeutics Ltd. | 22.04 Million USD | -967.166% |
| Rhythm Pharmaceuticals, Inc. | 162.98 Million USD | -44.315% |
| Nuvalent, Inc. | 31.82 Million USD | -639.132% |
| ABVC BioPharma, Inc. | 6.36 Million USD | -3597.387% |
| Carisma Therapeutics, Inc. | 63.02 Million USD | -273.225% |
| Unicycive Therapeutics, Inc. | 18 Million USD | -1206.744% |
| OmniAb, Inc. | 87.4 Million USD | -169.124% |
| Anew Medical, Inc. | 8.24 Million USD | -2753.916% |
| Fennec Pharmaceuticals Inc. | 38.28 Million USD | -514.311% |
| Lipocine Inc. | 2.63 Million USD | -8837.962% |
| Lexeo Therapeutics, Inc. Common Stock | 26.27 Million USD | -795.303% |
| Nautilus Biotechnology, Inc. | 40.21 Million USD | -484.935% |
| SAB Biotherapeutics, Inc. | 26.64 Million USD | -782.875% |
| G1 Therapeutics, Inc. | 86.15 Million USD | -173.016% |
| Bellerophon Therapeutics, Inc. | 5.4 Million USD | -4255.008% |
| Sage Therapeutics, Inc. | 82.74 Million USD | -184.257% |
| Ocugen, Inc. | 23.98 Million USD | -880.753% |
| Mind Medicine (MindMed) Inc. | 46.4 Million USD | -406.85% |
| Q32 Bio Inc. | 233.12 Million USD | -0.895% |
| Brainstorm Cell Therapeutics Inc. | 9.06 Million USD | -2494.463% |
| Alumis Inc. Common Stock | 53.5 Million USD | -339.636% |
| Equillium, Inc. | 27.95 Million USD | -741.342% |
| Kyverna Therapeutics, Inc. | 206.59 Million USD | -13.854% |
| Coya Therapeutics, Inc. | 5.62 Million USD | -4080.345% |
| CNS Pharmaceuticals, Inc. | 6.13 Million USD | -3735.239% |
| Galera Therapeutics, Inc. | 157.32 Million USD | -49.507% |
| Evelo Biosciences, Inc. | 69.43 Million USD | -238.764% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -2258.224% |
| Dominari Holdings Inc. | 4.63 Million USD | -4974.736% |
| Edesa Biotech, Inc. | 1.84 Million USD | -12672.007% |
| vTv Therapeutics Inc. | 29.56 Million USD | -695.529% |
| Bio-Techne Corporation | 744.34 Million USD | 68.4% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -86.531% |
| Harmony Biosciences Holdings, Inc. | 344.45 Million USD | 31.714% |
| Prelude Therapeutics Incorporated | 40.57 Million USD | -479.702% |
| Candel Therapeutics, Inc. | 28.95 Million USD | -712.287% |
| iTeos Therapeutics, Inc. | 92.36 Million USD | -154.671% |
| Nkarta, Inc. | 105.6 Million USD | -122.741% |
| BioCardia, Inc. | 4.59 Million USD | -5024.488% |
| Iterum Therapeutics plc | 32.66 Million USD | -620.146% |